

The Blogosphere

```
151 □

» Links to here

Get this widget
POWERED BY □ Technorati
```

Federal Appeals Court Denies Cook Biotech's and Purdue Research Foundation's Petition for Rehearing in ACell's Victory on Patent Infringement

Sat, 21 Oct 2006 01:03:46 -0700 PDT **bv Aria Munro**



JESSUP, Md. — ACell, Inc., the owner of highly valued extracellular matrix (ECM) patents, along with co-defendants Dr. Stephen Badylak and Dr. Alan Spievack, today won another legal victory against Cook Biotech, Inc. (Cook) and Purdue Research Foundation (Purdue) when the Court of Appeals for the Federal Circuit denied Cook's and Purdue's Petition for Rehearing and Rehearing En Banc. In the Petition Cook and Purdue had requested both the original Federal Circuit three judge panel and the entire Federal Circuit Court to reconsider a detailed 29 page written opinion issued on August 18, 2006.

In that opinion the three judge panel unanimously reversed a July 2005 finding against ACell of patent infringement, holding instead that ACell's product does not infringe Purdue's patent. The Federal Circuit is the federal court which specializes in patent law and provides guidance to federal district courts on patent law issues.

ACell's ECM is a graft material that can be implanted at the site of an injury or damaged tissue in order to stimulate a unique healing response. The graft attracts the body's own progenitor cells which have the potential to diversify into site specific tissues. Consequently, instead of the body's default healing mechanism of scar tissue formation, the body heals by remodeling with new

Related Stories:

Federal Appeals
Court Overturns
Infringement
Verdict Against
ACell and Rejects
Purdue Research
Foundation's Appeal
of Patent
Inventorship

1-800-SKI VAIL Wins Trademark Suit with Vail Ski Area

Plaintiff Southwest Feed Alleges 'Unjust Land Grab' by State of Arizona in Excess of \$3 Million

The Original Patent
Troll Returns

Proposed Public
Agency
Accountability
Ballot Measure in

tissue almost as if the injury had never occurred. Because ACell already has multiple Food and Drug Administration (FDA) approvals allowing its ECM to be placed in humans, the victorious conclusion of this litigation eliminates a major hurdle to the use of ACell's technology for solving a wide range of medical problems in various fields including orthopedics, cardiovascular, urology, gastrointestinal, general surgery and wound care.

"ACell's plan is to accelerate the development and commercialization of advanced medical therapies involving our unique ECM technology by partnering with leading companies in the life sciences industry," explained Jim DeFrancesco, ACell's CEO and President. "This litigation was the biggest impediment to our ability to finalize partnerships. The difference in the way we are being perceived within the industry now that these victories are behind us is remarkable. We are delighted to finally be receiving the attention that we always felt we deserved."

Miles Grody, ACell's Chief Operating Officer and General Counsel, commented "Cook and Purdue have had their day in court, and there can be no question now that ACell's technology is completely independent of the claims they have made. Despite extensive document reviews and depositions during this three year litigation they failed to raise any legitimate material issue of fact meriting a trial. This attempt by Cook and Purdue to deprive ACell of its proprietary technology has completely failed, and we are glad to have it behind us."

About ACell, Inc.

ACell, Inc. was incorporated in Delaware in June 1999 for the purpose of developing, manufacturing, and marketing products in the field of regenerative medicine. These tissue engineered products are based on naturally occurring ECM scaffolds. The Company's proprietary ECM technology changes the fundamental healing response by encouraging the body's own regenerative capabilities to repair tissues and restore them to natural health.

ACell's business plan involves building strategic relationships with leading companies in the life sciences field to make valuable ECM products available across a broad range of medical applications.

More information: www.acell.com

Technorati Tags: ACell Inc, ECM technology, biotech patent, life sciences field, extracellular matrix

SPHERE: Related Content — CLICK HERE to See What Else is Out There!

About The Author / Editor:

Aria C. Munro works in the book publishing industry and has been a content editor for the Neotrope News Network since 2004. Her black video iPod is most often shuffling Invader Zim episode vids and Thomas Dolby or Dead Can Dance tunez.

» Learn More About Aria Munro

This material is Copr. © 2006 eNewsChannels™ and Neotrope® - Terms of Use

IMPORTANT NOTE — **For questions or comments about this news story:** contact the company mentioned in the above article, and NOT this Website. eNewsChannelsTM cannot assist you with additional information about the company, product(s), or service(s) mentioned in the story. Information is not guaranteed to be accurate nor current.

Share this news story with your social network:



Permalink: http://enewschannels.com/2006/10/21/enc327 010346.php

Story is found in these categories:

News: Biotech and Biometric, News: Legal, State: Maryland, Story Index

This page looks best with screen set to 1024x768 or larger.

Advertisements –



Litigation Attorneys

Find more sources/options for Litigation Attorneys

Litigation Software

Visualize, structure and assess complex legal cases.

v v

Ads by Google

Promote Your Company to the Media and on This Website

Press release services and Internet marketing from Neotrope® Proven, targeted solutions since 1983 • Member BBB » Press Release Writing **» Targeted News Distribution**

Related Articles and News Stories:

Federal Appeals Court Overturns Infringement Verdict Against ACell and Rejects Purdue Research Foundation's Appeal of Patent Inventorship

1-800-SKI VAIL Wins Trademark Suit with Vail Ski Area

Plaintiff Southwest Feed Alleges 'Unjust Land Grab' by State of Arizona in Excess of \$3 Million

The Original Patent Troll Returns

Proposed Public Agency Accountability Ballot Measure in California

CLICK HERE for Latest Content from eNewsChannels

Story References: » Federal Appeals Court Denies Cook Biotech's and Purdue Research Foundation's Petition for Rehearing in ACell's Victory on Patent Infringement, by Aria Munro, ACell, biotech, Jim DeFrancesco, extracellular matrix patent lawsuit decision, ECM technology, Sat, 21 Oct 2006, © $eNewsChannels^{TM}$

No Comments >>

No comments yet.
RSS feed for comments on this post.
Leave a comment
REAL NAME (required)
EMAIL (required)
POOKYESS Anti-spam word (required)
» Privacy Statement. The requested information is used only to prevent abuse.
NOTE: All comments are moderated and comment-spam will be IP blocked. Comments which are blatant attacks on a company or brand mentioned in the article will be ignored. Please comment intelligently and responsibly.
Press me now
Previous and Next Stories in This Category: « MyImmigrationStory.com lets Immigrants Tell Their Own Stories New Health Book for IBD Sufferers: 'Check Your Pride at the Door' »
Top of Page Home Page RSS 2.0 Feed XML A9 SiteInfo Toolbar XML Privacy Statement
Copyright © 1983 - 2008 Neotrope® - All Rights Reserved Part of the Neotrope® News Network Content may not be re-purposed, re-posted or broadcast without express permission. eNewsChannels TM is a trademark of NEOTROPE® - All Rights Reserved TERMS OF USE FOR CONTENT FOUND ON THIS SITE

http://enewschannels.com/2006/10/21/enc327_010346.php